ReviewJournal of inflammation research2026
Intestinal Ultrasound in Inflammatory Bowel Disease: Monitoring Inflammation and Treatment Response.
Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Inflammatory bowel disease (IBD), including Crohn's disease and Ulcerative Colitis, is a chronic immune-mediated condition that requires long-term monitoring to prevent disease progression and complications. The adoption of treat-to-target strategies has highlighted the limitations of symptom-based assessment and the need for objective tools to evaluate both mucosal and transmural inflammation. In this setting, cross-sectional imaging has gained relevance, and intestinal ultrasound (IUS) has emerged as a noninvasive point-of-care modality for disease monitoring. Aims and Methods: As the evidence of IUS in the monitoring of IBD continues to expand, we provided a comprehensive overview of its clinical applications and supporting evidence.This narrative review summarizes the current evidence regarding the role of IUS in monitoring therapeutic response in IBD including results of retrospective and prospective studies and meta-analyses. Results: The IUS demonstrates high diagnostic accuracy in assessing inflammatory activity in both Crohn's disease and ulcerative colitis, with strong correlations with endoscopic and biochemical markers. In Crohn's disease, IUS enables early detection of treatment response to biologic and small-molecule therapies, assessment of transmural healing, and identification of complications such as strictures, fistulas, and abscesses. In ulcerative colitis, IUS has been shown to predict endoscopic remission, clinical response, and long-term outcomes, including the risk of colectomy. Early ultrasound assessment is also valuable in acute severe ulcerative colitis, identifying corticosteroid responses, and the need for rescue therapy or surgery. Several ultrasound-based scoring systems have been proposed; however, only a limited number have undergone robust external validation, and definitions of response and remission remain heterogeneous. Overall, IUS represents a valuable tool for personalized disease monitoring, although wider standardization using validated scores is required for broader implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.